<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN"
       "https://jats.nlm.nih.gov/publishing/1.3/JATS-journalpublishing1-3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" dtd-version="1.3" article-type="research-article" xml:lang="en">
 <front>
  <journal-meta>
   <journal-id journal-id-type="nlm-ta">Ulutas Med J</journal-id>
   <journal-title-group>
    <journal-title>The Ulutas Medical Journal</journal-title>
    <abbrev-journal-title>Ulutas Med J</abbrev-journal-title>
   </journal-title-group>
   <issn pub-type="ppub">2149-0430</issn>
   <issn pub-type="epub">2149-388X</issn>
   <publisher>
    <publisher-name>Hayriye Zehra Ulutaş</publisher-name>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="doi">10.5455/umj.20150924034203</article-id>
   <article-id pub-id-type="publisher-id">201623</article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>Original Research</subject>
    </subj-group>
    <subj-group subj-group-type="subject">
     <subject>Biochemistry</subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title>Impact of glycemic status on left ventricular systolic function in patients with acute coronary syndrome</article-title>
   </title-group>
   <contrib-group>
    <contrib contrib-type="author" corresp="yes">
     <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1190-2731</contrib-id>
     <name name-style="western">
      <surname>Amin</surname>
      <given-names>Alaaeldin Abdelhady</given-names>
     </name>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
     <xref ref-type="aff" rid="aff1">1</xref>
    </contrib>
    <contrib contrib-type="author">
     <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8596-4869</contrib-id>
     <name name-style="western">
      <surname>Ammar</surname>
      <given-names>Waleed Abdelsalam</given-names>
     </name>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
     <xref ref-type="aff" rid="aff1">1</xref>
    </contrib>
    <contrib contrib-type="author">
     <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8901-4673</contrib-id>
     <name name-style="western">
      <surname>Farrag</surname>
      <given-names>Azza Abdelmoniem</given-names>
     </name>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
     <xref ref-type="aff" rid="aff1">1</xref>
    </contrib>
    <aff id="aff1">
     <label>1</label>
     <institution-wrap>
      <institution-id institution-id-type="ror">https://ror.org/03q21mh05</institution-id>
      <institution>Department of Cardiovascular Medicine, Cairo University, Cairo, Egypt</institution>
     </institution-wrap>
    </aff>
   </contrib-group>
   <pub-date publication-format="electronic" date-type="pub" iso-8601-date="2015-09-25">
    <day>25</day>
    <month>09</month>
    <year>2015</year>
   </pub-date>
   <pub-date publication-format="print" date-type="collection">
    <year>2015</year>
   </pub-date>
   <volume>1</volume>
   <issue>3</issue>
   <fpage>58</fpage>
   <lpage>63</lpage>
   <history>
    <date date-type="received" iso-8601-date="2015-07-12">
     <day>12</day>
     <month>07</month>
     <year>2015</year>
    </date>
    <date date-type="rev-recd" iso-8601-date="2015-08-19">
     <day>19</day>
     <month>08</month>
     <year>2015</year>
    </date>
    <date date-type="accepted" iso-8601-date="2015-08-28">
     <day>28</day>
     <month>08</month>
     <year>2015</year>
    </date>
   </history>
   <permissions>
    <copyright-statement>© 2015 The Author(s)</copyright-statement>
    <copyright-year>2015</copyright-year>
    <license>
     <ali:license_ref>https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
     <license-p>This is an open access article distributed under the CC BY-NC 4.0 licence.</license-p>
    </license>
   </permissions>
   <self-uri xlink:href="https://www.ulutasmedicaljournal.com/?mno=201623"/>
   <self-uri content-type="pdf" xlink:href="https://www.ulutasmedicaljournal.com/pdf/201623.pdf"/>
   <abstract>
    <p>Background: Diabetes mellitus (DM) and left ventricular systolic dysfunction (LVSD) commonly coexist; increasing morbidity and mortality among patients. The aim of this study is to detect the correlation between the glycemic status of patients presenting by acute coronary syndrome (ACS) and left ventricular global and regional systolic function. Method: The study included 510 patients presenting by ACS and referred for coronary angiography. In addition to routine laboratory tests, Glycated hemoglobin (HbA1C) level, as a marker of chronic glycemic status, was measured. Every patient was subjected to transthoracic echocardiographic study with accurate evaluation of left ventricular systolic function by both m-mode and biplane Simpson's method, in addition to calculation of regional wall motion score index (RWMSI). The whole study population was divided into two groups; diabetic and non-diabetic based on cutoff point of HbA1C value 6.5%. The non-diabetic group was subdivided into two groups; high risk and low risk based on cutoff point of HbA1C value 5.7% Results: Sixty four percent of the studied population had DM. The mean HbA1C level was 7.6 ± 2.2%. The mean left ventricular ejection fraction (LVEF) was 54 ± 11 and mean RWMSI was 1.3 ± 0.3. There was significant negative correlation between the HbA1C level and the LVEF (r = -0.101, p &lt; 0.022). There was significant positive correlation between HbA1C level and RWMSI (r = 0.109, p &lt; 0.014). The non-diabetic high risk group had lower LVEF and higher RWMSI than the low risk group (p &lt; 0.041 and p &lt; 0.002 respectively). Conclusion: Chronic hyperglycemia in patients with uncontrolled DM may be a risk factor for developing LVSD in patients presenting by ACS. Glycated hemoglobin level may predict LVSD in patients with ACS. Non-diabetic patients who are at higher risk of developing DM have higher incidence of LVSD.</p>
   </abstract>
   <kwd-group kwd-group-type="author">
    <kwd>Diabetes mellitus</kwd>
    <kwd>glycated hemoglobin</kwd>
    <kwd>ejection fraction</kwd>
    <kwd>acute coronary syndrome</kwd>
   </kwd-group>
   <funding-group>
    <funding-statement>Funding information was not reported in the published version of this article.</funding-statement>
   </funding-group>
  </article-meta>
 </front>
 <body>
  <sec id="sec-1">
   <title>Introduction</title>
   <p id="b-1">Cardiovascular diseases (CVD), including heart failure and coronary artery disease (CAD), are the major causes of morbidity and mortality in patients with type 2 diabetes mellitus (DM) (    <xref ref-type="bibr" rid="ref1">1</xref>
,    <xref ref-type="bibr" rid="ref2">2</xref>
). Diabetic patients usually present several factors contributing to the risk of CVD, which include hyperglycemia, insulin resistance, dyslipidemia and hypertension (    <xref ref-type="bibr" rid="ref1">1</xref>
).</p>
   <p id="b-2">Apart from CAD as a major determinant of cardiomyopathy in diabetic patients, several studies demonstrated other pathophysiological mechanisms that alter the cardiac structure and promote myocardial fibrosis. These mechanisms include changes in free acid metabolism, increased oxidative stress, apoptosis and activation of the renin-angiotensin system (    <xref ref-type="bibr" rid="ref3">3</xref>
). The contribution of these factors to left ventricular systolic dysfunction (LVSD) in patients with CAD remains unclear. Glycated hemoglobin (HbA1C) level reflects the average blood glucose concentrations over a period of two to three months. The measurement of HbA1C is well standardized with less biologic variability than fasting and postprandial plasma glucose levels. It is considered a marker of chronic glycemic status and used for monitoring efficacy of antidiabetic medications (    <xref ref-type="bibr" rid="ref4">4</xref>
).</p>
   <p id="b-3">The relationship between HbA1C and CVD remains controversial (    <xref ref-type="bibr" rid="ref5">5</xref>
). In ARIC study; HbA1C values showed a J-shaped association with the incidence of heart failure (    <xref ref-type="bibr" rid="ref6">6</xref>
). Even among non-diabetics, the prediabetic state has been demonstrated to increase the risk for LVSD (    <xref ref-type="bibr" rid="ref7">7</xref>
,    <xref ref-type="bibr" rid="ref8">8</xref>
). In the present study, we examined the correlation between the level of HbA1C and left ventricular systolic function in both diabetic and non-diabetic patients at time of presentation by an acute coronary syndrome (ACS).</p>
  </sec>
  <sec id="sec-2">
   <title>Study Design</title>
   <p id="b-4">The study population included 510 patients presenting by an ACS to four tertiary centers over a period of one year. All patients were subjected to medical history taking and clinical examination. Cardiovascular risk factors as smoking, DM, hypertension, obesity and family history of CAD were reported. The study protocol was approved by the local ethics committee.</p>
   <p id="b-5">All patients presenting by an ACS fulfilling any of the following criteria were included in the study: Typical anginal symptoms, electrocardiographic changes suggestive of ischemia, echocardiographic evidence of segmental wall motion abnormalities, Positive cardiac biomarkers and angiographic evidence of CAD.</p>
   <p id="b-6">Blood samples were taken at the time of admission for HbA1C, serum creatinine in addition to other routine laboratory measurements. Samples for fasting plasma glucose (FPG) were taken after eight hour fast. Glycated hemoglobin level was assessed quantitatively using Siemens Dimension Xpand Plus assay and results were reported as percentage of total hemoglobin.</p>
   <p id="b-7">The diagnosis of DM was based on the recent American Diabetes Association (ADA) recommendations for classification and diagnosis of DM (    <xref ref-type="bibr" rid="ref9">9</xref>
). The criteria used for diagnosis were: FPG ≥126 mg/dL (7.0 mmol/L) and/or HbA1C ≥ 6.5%. If the two tests were concordant for the diagnosis of DM, additional testing was not needed. If the two tests were discordant, the test that was diagnostic of DM was repeated on the next day to confirm the diagnosis.</p>
   <p id="b-8">Diabetic patients were classified into controlled and uncontrolled groups based on the cutoff point of HbA1C value 7%. While non-diabetic patients were classified as low and high risk groups for development of DM based on cutoff point of HbA1C value 5.7%.</p>
   <sec id="sec-3">
    <title>Transthoracic echocardiography</title>
    <p id="b-9">Left ventricular internal dimensions and wall thickness were measured through standard parasternal short axis view using M-mode pattern (     <xref ref-type="bibr" rid="ref10">10</xref>
). Left ventricular ejection fraction (LVEF) was measured using biplane Simpson’s method (     <xref ref-type="bibr" rid="ref10">10</xref>
) in the apical four chamber and apical two chamber views. Simpson’s algorithm divides the left ventricle into a series of stacked oval disks and the volume of the entire left ventricle can be derived from the sum of the volume of the individual disks through a formula integrated within the software package of the echocardiographic machine (     <italic>Figure-1</italic>
).</p>
    <p id="b-10">Qualitative assessment of the segmental wall motion abnormalities at rest was done. Each myocardial segment was given a score as follows: 1 for normal contraction or hyperkinesia, 2 for hypokinesis (reduced thickening), 3 for akinesia (absent or negligible thickening as scar), 4 for dyskinesia (systolic thinning or stretching including aneurysmal segments). Regional wall motion score index (RWMSI) was then calculated as sum of all scores divided by the number of segments visualized. The echocardiographic machine used was Philips ultrasound system (IE33, Best, Netherlands). All measurements were reported as per American Society of Echocardiography (ASE) guidelines and recommendations (     <xref ref-type="bibr" rid="ref10">10</xref>
).</p>
   </sec>
   <sec id="sec-4">
    <title>Statistical analysis</title>
    <p id="b-11">All statistical analyses were performed using SPSS for windows with statistical package version 18. Normally distributed continuous variables were represented as mean ±SD, or as the percentage of the sample. Fisher’s exact test will be used to determine differences in patient characteristics.</p>
    <p id="b-12">Comparison between diabetic and non-diabetic groups was done using two-tailed unpaired student t test for continuous variables and the Pearson's chi-square test for categorical variables. Correlations between normally distributed variables were done using Pearson correlation coefficient. A p value &lt; 0.05 was considered significant for all tests.</p>
   </sec>
  </sec>
  <sec id="sec-5">
   <title>Results</title>
   <p id="b-13">Baseline clinical characteristics, laboratory and echocardiographic data of the whole study participants are listed in     <italic>Table-1</italic>
 and     <italic>Table-2</italic>
. Male gender presented 85.1% of the sample. Baseline clinical characteristics, laboratory and echocardiographic data of diabetic and non-diabetic groups are listed in     <italic>Table-3</italic>
 and     <italic>Table-4</italic>
. Both diabetic and non-diabetic groups had comparable gender distribution, prevalence of obesity and clinical presentation. However, diabetic patients were older and had more prevalence of hypertension.</p>
   <p id="b-14">The majority of diabetic patients (71%) had poorly controlled DM. Diabetic patients had high levels of HbA1C and FPG at time of presentation for coronary angiography (Mean values: 8.6±2.2 and 145±42, respectively). They also had lower HDL cholesterol and lower creatinine clearance (    <italic>p</italic>
 = 0.014 and     <italic>p</italic>
=0.002, respectively). Diabetic patients had higher RWMSI in comparison with non-diabetic patients (    <italic>p</italic>
 = 0.033).</p>
   <table-wrap id="tbl-1" position="float">
    <label>Table 1</label>
    <caption>
     <title>Baseline clinical characteristics of the participants</title>
    </caption>
    <graphic xlink:href="tbl-1.png">
     <alt-text>Table 1: Baseline clinical characteristics of the participants</alt-text>
    </graphic>
   </table-wrap>
  </sec>
  <sec id="sec-6">
   <title>Clinical Presentation</title>
   <p id="b-15">Baseline clinical and echocardiographic data of low risk and high risk non-diabetic patients are listed in Table 5. High risk non-diabetic patients had significantly lower LVEF and higher RWMSI (    <italic>p</italic>
=0.041 and     <italic>p</italic>
=0.002 respectively). There was negative correlation between HbA1C level and LVEF (r= -0.101,     <italic>p</italic>
&lt;0.022)(    <italic>Figure-2</italic>
). There was positive correlation between HbA1C and RWMSI (r= 0.109,     <italic>p</italic>
&lt;0.014)(    <italic>Figure-3</italic>
).</p>
   <table-wrap id="tbl-2" position="float">
    <label>Table 2</label>
    <caption>
     <title>Baseline Laboratory and echocardiographic data of the whole study participants</title>
    </caption>
    <graphic xlink:href="tbl-2.png">
     <alt-text>Table 2: Baseline Laboratory and echocardiographic data of the whole study participants</alt-text>
    </graphic>
   </table-wrap>
   <table-wrap id="tbl-3" position="float">
    <label>Table 3</label>
    <caption>
     <title>Baseline clinical and demographic characteristics of diabetic and non-diabetic groups</title>
    </caption>
    <graphic xlink:href="tbl-3.png">
     <alt-text>Table 3: Baseline clinical and demographic characteristics of diabetic and non-diabetic groups</alt-text>
    </graphic>
   </table-wrap>
   <table-wrap id="tbl-4" position="float">
    <label>Table 4</label>
    <caption>
     <title>Laboratory and echocardiographic data of diabetic and non-diabetic groups</title>
    </caption>
    <graphic xlink:href="tbl-4.png">
     <alt-text>Table 4: Laboratory and echocardiographic data of diabetic and non-diabetic groups</alt-text>
    </graphic>
   </table-wrap>
   <table-wrap id="tbl-5" position="float">
    <label>Table 5</label>
    <caption>
     <title>Clinical and echocardiographic data of low risk and high risk non-diabetic patients</title>
    </caption>
    <graphic xlink:href="tbl-5.png">
     <alt-text>Table 5: Clinical and echocardiographic data of low risk and high risk non-diabetic patients</alt-text>
    </graphic>
   </table-wrap>
   <fig id="fig-1" position="float">
    <label>Figure 1</label>
    <caption>
     <p>Left ventricular ejection fraction by biplane Simpson’s method. Upper panel shows apical 4 chamber view while lower panel shows apical two chamber view (end-diastolic and end-systolic frames).</p>
    </caption>
    <graphic xlink:href="fig-1.png">
     <alt-text>Figure 1: Left ventricular ejection fraction by biplane Simpson’s method. Upper panel shows apical 4 chamber view while lower panel shows apical two chamber view (end-diastolic and end-systolic frames).</alt-text>
    </graphic>
   </fig>
   <p id="b-16">
    <bold>c M</bold>
   </p>
   <fig id="fig-2" position="float">
    <label>Figure 2</label>
    <caption>
     <p>Correlation between HbA1c level and LVEF</p>
    </caption>
    <graphic xlink:href="fig-2.png">
     <alt-text>Figure 2: Correlation between HbA1c level and LVEF</alt-text>
    </graphic>
   </fig>
   <fig id="fig-3" position="float">
    <label>Figure 3</label>
    <caption>
     <p>Correlation between HbA1c level and RWMSI</p>
    </caption>
    <graphic xlink:href="fig-3.png">
     <alt-text>Figure 3: Correlation between HbA1c level and RWMSI</alt-text>
    </graphic>
   </fig>
  </sec>
  <sec id="sec-7">
   <title>Discussion</title>
   <p id="b-17">Several studies demonstrated a clear association between DM and left ventricular dysfunction even in absence of significant CAD. Most of these studies emphasize the presence of left ventricular diastolic dysfunction and increased LV filling pressure. Tsai JP et al (    <xref ref-type="bibr" rid="ref11">11</xref>
) study recently recruited 142 patients with first incidence of STEMI. The study concluded that HbA1C is independently associated with impaired LV diastolic function and increased filling pressures after STEMI. In a cross sectional study of 100 patients with newly diagnosed type 2 DM, Sanjeev Kumar et al (    <xref ref-type="bibr" rid="ref12">12</xref>
) reported a significant positive correlation between HbA1C and presence of left ventricular diastolic dysfunction (    <italic>p</italic>
=0.0157).</p>
   <p id="b-18">Few studies however examined the association between glycemic status and LVSD. The level of HbA1C is used as a target of glycemic control to reduce microvascular complications; however its correlation with CVD is not well established. In the present study, the HbA1C level was significantly correlated with the LVEF as an important parameter of global left ventricular systolic functions.</p>
   <p id="b-19">In a recent study (    <xref ref-type="bibr" rid="ref13">13</xref>
), a linear decrease in LVEF was found with raised level of HbA1C in patients presented with unstable angina, STEMI and NSTEMI (    <italic>p</italic>
=0.0043,     <italic>p</italic>
=0.029 and     <italic>p</italic>
=0.0015 respectively). Patients with HbA1C value ≥ 6.5% had significantly lower LVEF compared with those of lower values (    <italic>p</italic>
=0.0001). In the present study, we included a larger number of patients (510 vs. 50 patients) and there was no significant difference in LVEF between diabetic and non-diabetic groups (based on cutoff point of HbA1C value 6.5%).</p>
   <p id="b-20">Another study conducted by Mayorga et al (    <xref ref-type="bibr" rid="ref14">14</xref>
) included patients with type 2 DM and first incidence of acute myocardial infarction. Glycated hemoglobin levels above 8.5% had a tendency to present with LVEF below 50% (    <italic>p </italic>
: 0.019). Our study included a larger number of diabetic patients (328 vs. 36 patients) and there was no significant difference in LVEF between controlled and uncontrolled diabetic patients (based on cutoff point of HbA1C value 7%).</p>
   <p id="b-21">Isabelle Pham et al (    <xref ref-type="bibr" rid="ref15">15</xref>
) conducted a study to assess the prevalence of subclinical diabetic cardiomyopathy occurring among diabetic patients. The study included 656 asymptomatic patients with type 2 DM and patients with CAD represented 11.1% of the study participants. Multivariate logistic regression analysis showed that HbA1C is an independent predictor of LVSD (OR 1.9; CI [1.1–3.2],     <italic>p</italic>
 &lt; 0.05). In the present study, diabetic patients were symptomatic and presented by an ACS. The subclinical alterations of cardiac structure and function might have an impact on the negative correlation between HbA1C level and LVEF at time of presentation.</p>
   <p id="b-22">Even among non-diabetic patients, a study (    <xref ref-type="bibr" rid="ref16">16</xref>
) of 200 patients presenting with ACS demonstrated a linear correlation between LVEF and HbA1C (    <italic>p</italic>
= 0.019). In our study, high risk non-diabetic patients had lower LVEF than low risk patients. Dan E. Høfsten et al (    <xref ref-type="bibr" rid="ref17">17</xref>
) study included 203 patients with impaired glucose tolerance and presenting by an acute myocardial infarction. After adjustment for confounding variables; including hypertension and dyslipidemia; a statistically significant linear correlation was observed between the degree of dysglycemia and LVEF (    <italic>p</italic>
=0.03). The impact of glycemic level on LVEF appears to be a continuum across the entire spectrum of sub-diabetic glycemic values.</p>
   <p id="b-23">Regional wall motion score index (RWMSI) reflects regional LVSD and correlates well with LVEF. Although not routinely measured, RWMSI can predict the severity of CAD. To our knowledge, the correlation between HbA1C level and RWMSI was not previously studied. In the present study, we demonstrated a significant positive correlation between both parameters (r :0.109,     <italic>p</italic>
&lt;0.014). Both diabetic and high risk non-diabetic patients had higher RWMSI. This further emphasizes the impact of glycemic status on both left ventricular function as well as the coronary artery affection.</p>
  </sec>
  <sec id="sec-8">
   <title>Conclusion</title>
   <p id="b-24">Chronic hyperglycemia in patients with uncontrolled DM may be a risk factor for developing LVSD in patients presenting by ACS. Glycated hemoglobin level may predict LVSD in patients with ACS. Non-diabetic patients who are at higher risk of developing DM have higher incidence of LVSD.</p>
   <sec id="sec-9">
    <title>Study limitations</title>
    <p id="b-25">All patients included in the study had evidence of CAD. The extent of regional and global LVSD might have been correlated with the extent of coronary artery affection. The pure impact of glycemic status on LVSD could not be ruled out.</p>
   </sec>
  </sec>
 </body>
 <back>
  <ref-list>
   <title>References</title>
   <ref id="ref1">
    <label>1</label>
    <mixed-citation publication-type="journal">Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R et al. American Heart Association; American Diabetes Association: Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007, 115 (1): 114-126.</mixed-citation>
   </ref>
   <ref id="ref2">
    <label>2</label>
    <mixed-citation publication-type="journal">Stolar MW, Chilton RJ: Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Clin Ther 2003; 25(B): B4 -31.</mixed-citation>
   </ref>
   <ref id="ref3">
    <label>3</label>
    <mixed-citation publication-type="journal">Mochizuki Y, Tanaka H, Matsumoto K, Sano H, Toki H, Shimoura H et al. Clinical features of subclinical left ventricular systolic dysfunction in patients with diabetes mellitus. Cardiovascular Diabetology 2015; 14: 37.</mixed-citation>
   </ref>
   <ref id="ref4">
    <label>4</label>
    <mixed-citation publication-type="journal">American Diabetes Association. Glycemic targets. Sec. 6 In Standards of Medical Care in Diabetes-2015. Diabetes Care 2015; 38 (S1): S33 - S40.</mixed-citation>
   </ref>
   <ref id="ref5">
    <label>5</label>
    <mixed-citation publication-type="journal">Bando YK, Murohara T.Diabetes-Related Heart Failure. Does Diabetic Cardiomyopathy Exist? Circ J 2014; 78: 576-583.</mixed-citation>
   </ref>
   <ref id="ref6">
    <label>6</label>
    <mixed-citation publication-type="journal">Matsushita K, Blecker S, Pazin-Filho A, Bertoni A, Chang PP, Coresh J et al. The association of hemoglobin A1c with incident heart failure among people without diabetes: The atherosclerosis risk in communities study. Diabetes 2010; 59: 2020-2026.</mixed-citation>
   </ref>
   <ref id="ref7">
    <label>7</label>
    <mixed-citation publication-type="journal">Banerjee D, Biggs ML, Mercer L, Mukamal K, Kaplan R, Barzilay J et al. Insulin resistance and risk of incident heart failure: Cardiovascular Health Study. Circ Heart Fail 2013; 6: 364-370.</mixed-citation>
   </ref>
   <ref id="ref8">
    <label>8</label>
    <mixed-citation publication-type="journal">Witteles RM, Fowler MB. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 2008; 51: 93-102.</mixed-citation>
   </ref>
   <ref id="ref9">
    <label>9</label>
    <mixed-citation publication-type="journal">American Diabetes Association. Classification and diagnosis of diabetes. Sec. 2 In Standards of Medical Care in Diabetes-2015. Diabetes Care 2015; 38 (S1): S8 – S16.</mixed-citation>
   </ref>
   <ref id="ref10">
    <label>10</label>
    <mixed-citation publication-type="journal">Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28: 1-39.</mixed-citation>
   </ref>
   <ref id="ref11">
    <label>11</label>
    <mixed-citation publication-type="journal">Tsai JP, Tian J, Wang WY, Ng AC. Glycated hemoglobin vs fasting plasma glucose as a predictor of left ventricular dysfunction after ST-elevation myocardial infarction. Can J Cardiol. 2015; 31 (1): 44-9</mixed-citation>
   </ref>
   <ref id="ref12">
    <label>12</label>
    <mixed-citation publication-type="journal">Kumar S, Aneja GK, Trivedi A, Atam V, Singh A, Panwar NV et al. Glycosylated Hemoglobin (HbA1c) is a reliable Predictor of left ventricular hypertrophy (LVH) and left ventricular diastolic dysfunction (LVDD) in newly diagnosed type 2 diabetic patients of western Uttar Pradesh. Int. J. Sci. Res. Publ 2014; 4 (12): 1-7</mixed-citation>
   </ref>
   <ref id="ref13">
    <label>13</label>
    <mixed-citation publication-type="journal">Abdul Razzaq MK, Rasheed JI, Mohmmad HS. The value of admission glucose and glycosylated hemoglobin in patients with acute coronary syndrome. IPMJ 2013; 12: 75-84.</mixed-citation>
   </ref>
   <ref id="ref14">
    <label>14</label>
    <mixed-citation publication-type="journal">Mayorga MP, Gomez-Arbelafez D, Melgarejo E, Bravo MA, Martinez A, Gonzalez LA et al. Relationship between Glycated Hemoglobin and Left ventricular ejection fraction in Diabetes type 2 patients on their first acute myocardial infarction. Rev.fac.med 2014; 22 (2): 12-19.</mixed-citation>
   </ref>
   <ref id="ref15">
    <label>15</label>
    <mixed-citation publication-type="journal">Pham I, Cosson E, Nguyen MT, Banu I, Genevois I, Poignard P et al. Evidence for a Specific Diabetic Cardio myopathy: An Observational Retrospective Echocardiographic Study in 656 Asymptomatic Type 2 Diabetic Patients. Int J Endocrinol 2015; 2015: 1-8.</mixed-citation>
   </ref>
   <ref id="ref16">
    <label>16</label>
    <mixed-citation publication-type="journal">Ashraf MU, Zaheer MS, Rabbani MU, Ashraf J, Aslam M. Impact of HbA1C on Outcomes of Acute Coronary Syndrome in Non-Diabetic Patients. J Cardiol. Therap.2014; 2(3):110-114.</mixed-citation>
   </ref>
   <ref id="ref17">
    <label>17</label>
    <mixed-citation publication-type="journal">Høfsten DE, Løgstrup BB, Møller JE, Pellikka PA, Egstrup K. Abnormal Glucose Metabolism in Acute Myocardial Infarction: Influence on Left Ventricular Function and Prognosis. JACC: Cardiovascular imaging 2009; 2(5): 592-599.</mixed-citation>
   </ref>
  </ref-list>
 </back>
</article>
